• DNA Nanotech Brings Precision Drug Monitoring to At-Home Use

    Nov 05 | Bio-IT World | For millions of patients prescribed drugs with a narrow therapeutic window, safe dosing depends on therapeutic drug monitoring. But outside of hospital labs equipped with specialized machines and trained staff, monitoring drug concentrations in real time has been largely out of reach. DNA nanotechnology may hold the key to bringing this critical capability to the point of care—and even into patients’ homes. More

  • PacBio Aims for Sub-$300 Genomes with Reusable SMRT Cells

    Nov 04 | Bio-IT World | Pacific Biosciences announced a chemistry upgrade and SMRT cell reuse capability last month at the American Society of Human Genetics (ASHG) meeting. CEO Christian Henry said the moves targeted dramatic price reductions for customers and to compete with short-read sequencing. More

  • NVIDIA Unveils Quantum-AI Integration and Record-Breaking Blackwell Architecture at GTC 2025

    Oct 30 | Bio-IT World | NVIDIA CEO Jensen Huang used NVIDIA’s GTC 2025 keynote to share his vision for the convergence of quantum computing and artificial intelligence, while revealing staggering demand for the company’s next-generation Grace Blackwell architecture that signals a fundamental shift in how the world computes. More

  • SandboxAQ Releases New AI Model, Illumina Launches New Business, Thermo Fisher’s New Analyzer

    Oct 29 | Bio-IT World | SandboxAQ releases AQCat25-EV2, a new quantitative AI model trained on the AQCat25 dataset; Illumina launches BioInsight, a new business within Illumina developed to meet industry demand for deeper biologic insights; Thermo Fisher Scientific introduces the Applied Biosystems SwiftArrayStudio Microarray Analyzer; and more. More

  • Follow the Money: Potential Best-in-Category Weight Loss Drug Tubulis’ ADC Advancement, Trojan Horse Treatment for Cancer

    Oct 28 | Bio-IT World | Kailera Therapeutics advances injectable dual GLP-1/GIP receptor agonist; Tubulis develops antibody-drug conjugate for ovarian cancer and lung adenocarcinomas; Trogenix advances their pipeline of potentially curative cancer therapies across multiple aggressive solid tumors into the clinic; and more. More

  • AI Model Turns Health Data Into Disease Forecasts

    Oct 23 | Bio-IT World | Researchers have developed a generative transformer model capable of forecasting an individual’s risk of developing over 1,200 diseases a decade in advance. The model, called Delphi-2M, was validated using data on about 2 million individuals from Denmark’s National Patient Registry without retraining. More

  • Multiomics Approach Predicts Rheumatoid Arthritis Before First Joint Swelling

    Oct 22 | Bio-IT World | A breakthrough in rheumatoid arthritis (RA) research may redefine how and when the autoimmune disease is diagnosed and treated. A team of researchers from the University of Colorado Anschutz., the Allen Institute for Immunology, and UC San Diego have mapped immune changes that occur years before the first swollen joint appears. More

  • Longitude Prize on ALS Announces Judge Panel

    Oct 21 | Bio-IT World | Last month, the Longitude Prize on ALS announced the judgement panel for the prize. The panel consists of leaders and experts from neuroscience, technology, and pharmaceutical fields from around the world. More

  • uniQure’s Huntington’s Disease Trial Shows Promising Results

    Oct 16 | Bio-IT World | Last month, uniQure announced promising results from their Phase I/II study of AMT-130, the company’s gene therapy to treat Huntington’s disease. A participant pool of 29 patients in the early stages of Huntington’s disease was categorized into two groups—low-dose and high-dose—and compared to a control group of 1,600 untreated Huntington’s patients at similar disease stages. More

  • New Immunotherapy Approach Hits the Sweet Spot with Solid Tumors

    Oct 15 | Bio-IT World | Glycans, the complex sugar chains found at abnormally high levels on the surface of cancer cells, have historically been difficult to target effectively with traditional antibody therapies. One of the biggest reasons is that T cells can’t present glycans to B cells so they can make antibodies that bind strongly and stably to the target antigen. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!